TCGA-LD-A7W5-01A-22R-A352-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- INTERFERON_ALPHA_RESPONSE+0.380
- INTERFERON_GAMMA_RESPONSE+0.370
- IL6_JAK_STAT3_SIGNALING+0.310
- MYOGENESIS+0.260
- KRAS_SIGNALING_DN+0.180
- COAGULATION+0.170
- WNT_BETA_CATENIN_SIGNALING+0.150
- APICAL_JUNCTION+0.100
- TNFA_SIGNALING_VIA_NFKB+0.100
Top 10 suppressed
- PROTEIN_SECRETION-0.560
- MTORC1_SIGNALING-0.480
- ANDROGEN_RESPONSE-0.450
- CHOLESTEROL_HOMEOSTASIS-0.410
- E2F_TARGETS-0.410
- MYC_TARGETS_V1-0.390
- OXIDATIVE_PHOSPHORYLATION-0.380
- G2M_CHECKPOINT-0.360
- GLYCOLYSIS-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311155 | — | — | 0.885 |
| 2 | SRR8518409 | — | D | 0.882 |
| 3 | MBCProject_0375_T1_B_RNA | — | D | 0.879 |
| 4 | MNG450 | — | — | 0.876 |
| 5 | TCGA-93-A4JO-01A-21R-A24X-07 | — | cohortA1 | 0.859 |
| 6 | MNG1248 | — | — | 0.857 |
| 7 | s0112296 | — | — | 0.855 |
| 8 | SRR8518166 | — | D | 0.855 |
| 9 | BS_G5QBBHDV | low-grade glioma | — | 0.852 |
| 10 | SRR12202481 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |